Robert  Veltri, Ph.D.
Robert Veltri, Ph.D.

Associate Professor of Urology
Johns Hopkins Medical Institutions

Address:
The Brady Urological Research Institute, Park Building, 213, 600 North Wolfe Street , Baltimore, MD 21287-2101

Appointments: (410) 955-6380

Email: rveltri1@jhmi.edu

Fax: (410) 502-7711

Licensure & Certification


PATENTS AND TRADEMARKS:

  1. Veltri RW, Maxim PE, Fodor G. 2-Furylbutyrolactone modulation of the immune system in mammals.  Patent No. 4,518,611 issued May 21, 1985Assigned to Theracel Corp., Rockville, MD.
  2. Maxim PE and Veltri RW. Assaying for circulating immune complexes with labeled protein A. Patent No. 4,617,262, Issued October 14, 1986. Assigned to CooperBiomedical Inc., Palo Alto, CA.
  3. Maxim PE and Veltri RW. Method of treating inflammation in mammals utilizing ketobutyrolactones and furylbutyrolactones. Patent No. 4,883,813, Issued November 28, 1989.  Assigned to Theracel Corp., Rockville, MD.
  4. Fodor G, Sussangkarn K. and Veltri RW. Condensation products of cyclic diketones and ascorbic acid as immunomodulatory agents.  Patent No. 4,883,808 issued November 28, 1989. Assigned to Theracel Corp., Rockville, MD.
  5. Fox, SW and Veltri RW. Microencapsulated antitumor agent. Patent No. 4,963,364, Issued October 16, 1990.  Assigned to the inventors.
  6. Veltri RW, Fodor G, and Sussangkarn K.  Pharmaceutically useful furyl substituted dihydroxyethylbutyrolactones. Patent No.  5,102,909 issued April 07, 1992. Assigned to Theracel Corp., Rockville, MD.
  7. Veltri RW and Fodor G.  Pharmaceutically useful Michael addition products of unsaturated aldehydes and ketones and ascorbic acid.  Patent No. 5,098,933 issued March 24, 1992. Assigned to Theracel Corp., Rockville, MD.
  8. Marley GM and Robert W. Veltri.  Methods for selectively inducing biomarker expression in urologic tumor tissue for diagnosis and treatment thereof.  Patent No. 5,856,112 issued January 5, 1999.  Assigned to UroCor Inc.
  9. Veltri RW, Bacus M, MC Miller, K Ashenayi, DP Coffey, AW Partin, and JI Epstein. (JHU Ref. C09828) entitled "Multivariate Statistical Modeling Biomarkers as Predictors of Recurrence Following Radical Prostatectomy".  Patent No. 6,025,128 issued February 15, 2000.
  10. Veltri RW, Miller MC, Bacus MP, Ashenayi K.  A sextant core biopsy predictive mechanism for non-organ-confined disease status".   Patent No. 5,989,811, Issued November 23, 1999. Assigned to UroCor, Inc.
  11. Veltri, Robert W., Ashenayi, Kaveh, Hu, Ying and O'Dowd, Gerard J.  Neural network for cell image analysis for identification of abnormal cells. Patent No. 6,463,438 issued October 8, 2002.  Assigned to UroCor, Inc., Oklahoma City, OK.
  12. Veltri RW, Bacus MP, Miller MC. Prediction of Prostate Cancer Progression by Analysis of Selected Biomarkers.  Patent No. 6,025 128, issued February15, 2000. Assigned to UroCor, Inc.
  13. An G, O'Hara SM, Ralph DA and Veltri RW. Biomarkers and targets for diagnosis, prognosis and management of prostate disease. Patent No. 5,882,864 issued March 16, 1999. Assigned to UroCor, Inc.
  14. An G, O'Hara SM, Ralph DA and Veltri RW. Biomarkers and targets for diagnosis, prognosis and management of prostate disease. US 2003/0050470 A1 issued March 13, 2003. Assigned to UroCor, Inc.
  15. Gang An and Robert W. Veltri.  Biomarkers and targets for diagnosis, prognosis and management of prostate diseases.  Patent No. 5,972,615. Issued October 26, 1999.  Assigned to UroCor, Inc., Oklahoma City, OK.
  16. Gang An, Veltri RW et al Biomarkers and targets for diagnosis, prognosis and management of prostate, breast, and bladder cancer.  Patent No. 6,218,529 issued on April 1,2001, Assigned to UroCor, Inc.
  17. Gang An and RW Veltri.  A novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer. Patent No. 6,156,515 Issued December 5, 2000. Assigned to UroCor.
  18. Gang An and RW Veltri.  Novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer. US 2003/0017472 A1 issued January 23, 2003. .  Assigned to UroCor, Inc. 
  19. Ralph DA, An G, and Veltri RW.  Diagnosis of disease state using mRNA profiles in peripheral leukocytes.    Patent No. 6,190,857 issued February 20, 2001.  Assigned to UroCor, Inc., Oklahoma City, OK. 
  20. An, Gang and Veltri, Robert. Prostate-specific gene for diagnosis, prognosis and management of prostate cancer. Patent No. 6,369,195 issued April 9, 2002. Assigned to UroCor, Inc., Oklahoma City, OK. 
  21. An, Gang and Veltri; Robert W. Biomarkers and targets for diagnosis prognosis and management of prostate disease. Patent No. 6,171,796 issued January 9, 2001 Assigned to UroCor, Inc.
  22. An, Gang and Robert Veltri. Novel, Prostate-Specific Gene for Diagnosis, Prognosis and Management of Prostate Cancer. Patent No. US 2008/ 0044416 A1 issued February 21, 2008. Assigned to UroCor, Inc.
  23. Veltri RW, Hui Zhang, Chris Christudass, Zhi Liu, John I. Epstein, and Ballantine Carter.    Provisional Patent Application Serial Number 61/888,648.  "Active Surveillance Biomarkers for Assessing Cancer Patients for Treatment" Filed with the United States Patent and Trademark Office on October 9, 2013.

Trademarks:

  1. Veltri RW. Trademark, "UroScoreTM". Serial No. 7468233 registered January 16, 1996 to UroCor Inc., Oklahoma City, OK.  Registration No. 1948820 for Laboratory research services in the field of oncology.
  2. Veltri RW. Trademark, Quantitative Nuclear Grade "QNGTM".  Serial No. 76173213 registered March 19, 2002 to UroCor Inc. of Oklahoma City, OK.  Registration No. 2549632 for Medical services for detecting, staging, and prognosis of cancer.

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved. Disclaimer
Email: webmaster@urology.jhu.edu | 600 North Wolfe Street, Baltimore, Maryland 21287

urology second opinion urology second opinion